At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 113 enrolled
Drug / intervention
MEDI9929 +1 morebiological
Likely dose
MEDI9929 280 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating MEDI9929 and Placebo for Atopic Dermatitis. Completed, enrolled 113 participants across 29 sites in 6 countries.
Detailed Summary
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, Germany, Hungary, New Zealand, United States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedAug 2015
Primary CompletionMay 2016
Study CompletionJul 2016
TodayJul 2026
First PostedAug 17, 2015
Enrollment StartAug 15, 2015
Primary CompletionMay 9, 2016
Study CompletionJul 15, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.9 years ago
Interventions
MEDI9929biological
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
Placebobiological
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.